menu
    • menu

    Company profile for Protalix BioTherapeutics

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx® plant cell-based protein expression system. Our pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix’s ProCellEx® platform has the abil...
    Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx® plant cell-based protein expression system. Our pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix’s ProCellEx® platform has the ability to manufacture complex proteins, antibodies, and vaccines and has the ability to orally deliver certain therapeutic proteins as demonstrated in animal models.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Protalix BioTherapeuticsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    2 Snunit St., Science Park, POB 455 Carmiel 2161401
    Telephone
    Telephone
    +972-4-902-8100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://protalix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/protalix-biotherapiutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protalix Biotherapeutics To Report FY2025 Financials
    Protalix Biotherapeutics To Report FY2025 Financials

    11 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2025-financial-results-and-business-update-on-march-18-2026-302710843.html

    PR NEWSWIRE
    11 Mar 2026
    Share Share
    Chiesi Global and Protalix Announce EU Approval Elfabrio
    Chiesi Global and Protalix Announce EU Approval Elfabrio

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251619/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Announce-European-Commission-Approval-of-Additional-Dosing-Regimen-of-Every-Four-Weeks-for-Elfabrio-pegunigalsidase-alfa.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229591/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Receive-Positive-CHMP-Opinion-for-an-Additional-Dosing-Regimen-of-Every-Four-Weeks-for-Elfabrio-pegunigalsidase-alfa-in-the.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Protalix Biotherapeutics Issues Letter to Stockholders
    Protalix Biotherapeutics Issues Letter to Stockholders

    05 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protalix-biotherapeutics-letter-to-stockholders-302652582.html

    PR NEWSWIRE
    05 Jan 2026
    Share Share
    Protalix Bio And Secarna Pharma Collaborate With Option Agreement
    Protalix Bio And Secarna Pharma Collaborate With Option Agreement

    17 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-secarna-pharmaceuticals-enter-into-collaboration-and-option-agreement-302644533.html

    PR NEWSWIRE
    17 Dec 2025
    Share Share
    Protalix Biotherapeutics Unveils Q3 2025 Financial Results
    Protalix Biotherapeutics Unveils Q3 2025 Financial Results

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-third-quarter-2025-financial-and-business-results-302614315.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Protalix BioTherapeutics and get a quotation

    Protalix BioTherapeutics is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Taliglucerase Alfa bulk offered by Protalix BioTherapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search